TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Plasma hepatocyte growth factor level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With >15 ETDRS Letter Loss at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Ophthalmic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: 180-min postprandial energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 180-min postprandial carbohydrate and fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-test-meal capillary blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in disease status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in quality of life questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rejection evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Patients With Treatment-induced Conversion of Atrial Fibrillation to Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Met Weight Loss Goal of 5% Weight Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of chromosomal anomalies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiac amyloidosis imaging results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cranio-caudal pituitary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Fecal Incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Tumor Response (Complete or Partial)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mood stabilization
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Annual change in BMI z-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with Adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Safety as determined by abnormality in haematology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety as determined by abnormality in clinical chemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as determined by abnormality in urinalysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety as determined by evaluation of blood pressure in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of non-covered stent struts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Completion rate of study parts
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants with Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in patient assessment using VAS survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Inter-rater reliability in aesthetic outcomes assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of aesthetic outcomes of umbilical reconstruction techniques
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Breast Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cortical mantle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in excitability of fronto-parietal connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone marrow tryptase level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neural function activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PRO compliance rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Serum concentration of bevacizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma free VEGF-A levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Engraftment Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of EPOR-STC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early lactation difficulties
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total glycated hemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline EULAR response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in best corrected visual acuity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PGC-1α mRNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arteries occluding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Infant neurodevelopment measured by Development quotient scores (DQS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in frequency of child maltreatment
Endpoint domain: Adverse events/effects
Primary endpoint: spatiotemporal spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of completed sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in luminal area gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Participants With Complete Response (CR) + Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of surgical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of Autonomic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sexual Encounter Profile (SEP) Question 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Sexual Encounter Profile (SEP) Question 3
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vasoconstrictor Responsiveness to Phenylephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Acceptability of endurance training program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of local vaccine-related clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of systemic vaccine-related clinical events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from pre-immunisation baseline values in body temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Cortisol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in QT and corrected QT (QTc) interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to exhaustion during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in peak power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TEG® parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: ROTEM® parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Rash
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of ototoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Contrast to Noise Ratio (CNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Good subjective health feeling of mother
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Dysphagia Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious Infections, Opportunistic Infections of Interest and Malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Required Subsequent Treatment With Etanercept or Other Systemic Therapies After Completion of Initial Treatment Period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Imaging of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Fourfold or Greater Post-vaccination Titers (Seroconversion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Viremic Participants Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Treatment-emergent Adverse Events Reported As Related to Study Treatment in at Least 5% of Participants in Any Active Treatment Group Post-vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Partial Onset Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurological Progression Free Survival (NPFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: The incidence of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of high risk people for colorectal cancer identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Performed colonoscopy rate within 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Total number of patients who passed away due to any cause at 1-year
Endpoint domain: Mortality/survival
Primary endpoint: Total number of patients who passed away due to any cause at 2-year
Endpoint domain: Mortality/survival
Primary endpoint: Total number of patients who passed away due to any cause at 3-year
Endpoint domain: Mortality/survival
Primary endpoint: Uterine fibroid size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent of Patients With a Greater Than or Equal to 10% Improvement in FEV1, FVC, and DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes of total gastroparesis symptom scores (TSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Virus negative conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Informed consent rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Protocol adherence rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of subjects achieving PBI ≥ 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective Contraception Initiation Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal-fetal transmission of CMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of searches/month/user
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cardiac output measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feeding Tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in proportion of never married adolescents
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in proportion of married adolescents
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Improvement in knee related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in function in sport and recreation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement of the Physician Global Assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HV interval correlation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall functional gain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak Torque (foot-pounds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to Discontinuation of Study Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: C-reactive protein level in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative sputum score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent baseline weight lost
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Hospital Admission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Thickness of lipid layers on patient cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thickness of aqueous layers on patient cornea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Collagen 1/3 ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With ppPASI 75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of hospitalized patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Length Tension Manometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Ashworth Scale-Bohannon (MAS-B) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Gastric emptying (antral area, cm2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: gingival crevicular fluid IL-34 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: proportion of subjects with diarrhea
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of subjects exhibiting 4-fold or greater rises in titers of serum vibriocidal antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adjusted Mean Change in Total Unified Parkinson Disease Rating Scale (UPDRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adjusted Mean Change in Adjusted UPDRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Counts of patients with epigenetic signatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Plasma TNF-alpha levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma pool volume of distribution for natural folates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants on LCIG Monotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clavien dindo>3
Endpoint domain: Adverse events/effects
Primary endpoint: Change in range of motion of first MTF joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in renal inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Continuous Complete Remission at 3 Years
Endpoint domain: Mortality/survival
Primary endpoint: Mortality Rate at 6 Weeks
Endpoint domain: Mortality/survival
Primary endpoint: Absorption kinetics of phenolic acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimum Mean Cell Viability Estimate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients with hypercalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with low parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Recurrent peptic ulcer bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Decision to remove X
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Progression-free Survival Greater Than 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Tumor Response Assessed by RECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Burns Specific Health Scale - Abbreviated (BSHS-A)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) On Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Glucose Area Under the Curve From Time 2 to 6 Hours (AUC [2-6]) After a Mixed Meal Tolerance Test (MMTT) at Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of development of Anti-drug Antibodies (ADAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Behavioural Inattention Test (BIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3 - years overall survival
Endpoint domain: Mortality/survival
Primary endpoint: 3 - years disease specific survival
Endpoint domain: Mortality/survival
Primary endpoint: 3 - years laryngeal function preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in morphology of Acne Scars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: ΔE (spectrophotometric outcome)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Bayley Scales of Infant Development (BSID) Score - Cognitive
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in stress-triggered response of catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline C-peptide response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from Baseline C-peptide after the MMTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficacy of EUS guided techniques for GFV treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genioglossus Activity During Sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CR-PCSS change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PR-PCSS change from baseline
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time of Healing (Days)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diagnosis efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Predicted Maximum Inspiratory Pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Venous carboxyhemoglobin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: HO-1 protein concentration in leukocytes from venous blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum bilirubin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of patients with a Complication risk
Endpoint domain: Adverse events/effects
Primary endpoint: proportion of clinical complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serial BNP values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of rDEN1delta30 vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity as assessed by neutralizing antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HER2/neu status association
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction of patient-determined hospital care at discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status